<?xml version='1.0' encoding='utf-8'?>
<document id="30280663"><sentence text="Drug-Drug Interactions of P-gp Substrates Unrelated to CYP Metabolism." /><sentence text="Recent US Food and Drug Administration (FDA) draft guidance on pharmacokinetic drugdrug interactions (DDIs) has highlighted the clinical importance of ABC transporters B1 or P-glycoprotein (P-gp), hepatic organic anion-transporting polypeptide transporters and breast cancer resistant protein because of their broad substrate specificity and the potential to be involved in DDIs" /><sentence text=" This guidance has indicated that digoxin, dabigatran etexilate and fexofenadine are P-gp substrate drugs and has defined P-gp inhibitors as those that increase the AUC of digoxin by â‰§1"><entity charOffset="34-41" id="DDI-PubMed.30280663.s3.e0" text="digoxin" /><entity charOffset="43-63" id="DDI-PubMed.30280663.s3.e1" text="dabigatran etexilate" /><entity charOffset="68-80" id="DDI-PubMed.30280663.s3.e2" text="fexofenadine" /><entity charOffset="172-179" id="DDI-PubMed.30280663.s3.e3" text="digoxin" /><pair ddi="false" e1="DDI-PubMed.30280663.s3.e0" e2="DDI-PubMed.30280663.s3.e0" /><pair ddi="false" e1="DDI-PubMed.30280663.s3.e0" e2="DDI-PubMed.30280663.s3.e1" /><pair ddi="false" e1="DDI-PubMed.30280663.s3.e0" e2="DDI-PubMed.30280663.s3.e2" /><pair ddi="false" e1="DDI-PubMed.30280663.s3.e0" e2="DDI-PubMed.30280663.s3.e3" /><pair ddi="false" e1="DDI-PubMed.30280663.s3.e1" e2="DDI-PubMed.30280663.s3.e1" /><pair ddi="false" e1="DDI-PubMed.30280663.s3.e1" e2="DDI-PubMed.30280663.s3.e2" /><pair ddi="false" e1="DDI-PubMed.30280663.s3.e1" e2="DDI-PubMed.30280663.s3.e3" /><pair ddi="false" e1="DDI-PubMed.30280663.s3.e2" e2="DDI-PubMed.30280663.s3.e2" /><pair ddi="false" e1="DDI-PubMed.30280663.s3.e2" e2="DDI-PubMed.30280663.s3.e3" /></sentence><sentence text="25-fold in clinical DDI studies" /><sentence text=" However, when substrate drugs of both CYPs and P-gp are involved in DDIs, it remains that the mechanisms of DDIs will be quite ambiguous in assessing how much the CYPs and/or drug transporters partially contribute to DDIs" /><sentence text="" /><sentence text="Since there are no detailed manuscripts that summarizes P-gp interactions unrelated to CYP metabolism, this article reviews the effects of potent P-gp inhibitors and P-gp inducers on the pharmacokinetics of P-gp substrate drugs, including digoxin, talinolol, dabigatran etexilate, and fexofenadine in human studies"><entity charOffset="239-246" id="DDI-PubMed.30280663.s7.e0" text="digoxin" /><entity charOffset="248-257" id="DDI-PubMed.30280663.s7.e1" text="talinolol" /><entity charOffset="259-279" id="DDI-PubMed.30280663.s7.e2" text="dabigatran etexilate" /><entity charOffset="285-297" id="DDI-PubMed.30280663.s7.e3" text="fexofenadine" /><pair ddi="false" e1="DDI-PubMed.30280663.s7.e0" e2="DDI-PubMed.30280663.s7.e0" /><pair ddi="false" e1="DDI-PubMed.30280663.s7.e0" e2="DDI-PubMed.30280663.s7.e1" /><pair ddi="false" e1="DDI-PubMed.30280663.s7.e0" e2="DDI-PubMed.30280663.s7.e2" /><pair ddi="false" e1="DDI-PubMed.30280663.s7.e0" e2="DDI-PubMed.30280663.s7.e3" /><pair ddi="false" e1="DDI-PubMed.30280663.s7.e1" e2="DDI-PubMed.30280663.s7.e1" /><pair ddi="false" e1="DDI-PubMed.30280663.s7.e1" e2="DDI-PubMed.30280663.s7.e2" /><pair ddi="false" e1="DDI-PubMed.30280663.s7.e1" e2="DDI-PubMed.30280663.s7.e3" /><pair ddi="false" e1="DDI-PubMed.30280663.s7.e2" e2="DDI-PubMed.30280663.s7.e2" /><pair ddi="false" e1="DDI-PubMed.30280663.s7.e2" e2="DDI-PubMed.30280663.s7.e3" /></sentence><sentence text=" In addition, the present outcome were to determine the PK changes caused by DDIs among P-gp substrate drugs without CYP metabolism in human DDI studies" /><sentence text="" /><sentence text="Our manuscript concludes that the PK changes of the DDIs among P-gp drugs unrelated to CYP metabolism are less likely to be serious, and it appears to be convincing that the absences of clinical effects caused to the PK changes by the P-gp inducers is predominant compared with the excessive effects caused to those by the P-gp inhibitors" /><sentence text="" /></document>